SEC Form SC 13G/A filed by Viking Therapeutics Inc. (Amendment)
$VKTX
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2024 | $90.00 → $102.00 | Buy | H.C. Wainwright |
| 9/11/2024 | $80.00 | Overweight | JP Morgan |
| 6/27/2024 | $105.00 | Overweight | Morgan Stanley |
| 5/16/2024 | $115.00 → $116.00 | Outperform → Strong Buy | Raymond James |
| 3/26/2024 | $116.00 → $138.00 | Outperform | Oppenheimer |
| 3/7/2024 | $110.00 | Buy | Jefferies |
| 2/28/2024 | $46.00 → $116.00 | Outperform | Oppenheimer |
| 5/31/2023 | $32.00 | Buy | ROTH MKM |
H.C. Wainwright reiterated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $102.00 from $90.00 previously
JP Morgan initiated coverage of Viking Therapeutics with a rating of Overweight and set a new price target of $80.00
Morgan Stanley initiated coverage of Viking Therapeutics with a rating of Overweight and set a new price target of $105.00
144 - Viking Therapeutics, Inc. (0001607678) (Subject)
8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
144 - Viking Therapeutics, Inc. (0001607678) (Subject)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
Oral Late Breaker Presentation Summarizes Positive Results Including Successful Achievement of Study's Primary and Secondary Endpoints Data Support VK2809's Best-in-Class Profile Highlighted by Robust Liver Fat Reductions, Histologic Results Demonstrating NASH/MASH Resolution and Fibrosis Improvement, and Promising Tolerability and Safety SAN DIEGO, Nov. 19, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that final results from the company's Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormo
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
Up to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Related Adverse Event Profile Updated Results from VENTURE Phase 2 Study of Subcutaneous VK2735 Show Durable Effects and Support Potential Monthly Dosing Regimen SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster present
HC Wainwright & Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $90 price target.
Shares of Indivior PLC (NASDAQ:INDV) rose sharply in today's pre-market trading after the company posted better-than-expected second-quarter results and announced an accelerated $100 million share repurchase program. Indivior reported quarterly earnings of 44 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million. Indivior shares jumped 14.5% to $12.46 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Psyence Biomedical Ltd. (NASDAQ:PBM) rose 157.4% to $1.00 in pre-market trading after the company
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
Conference call scheduled for 4:30 p.m. ET today End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH With Fibrosis Selected for Oral Presentation at AASLDPositive Phase 1b Results from VK0214 Study in X-ALD Demonstrate Safety, Tolerability and Reductions in Very Long-Chain Fatty Acids and Plasma LipidsStrong Quarter-End Cash Position of $930 MillionSAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrin
Conference Call Scheduled for Wednesday, October 23 at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the third quarter 2024 after the market close on Wednesday, October 23, 2024. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on